Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03387813 · ClinicalTrials.gov registry record · NA
Hemodynamic-GUIDEd Management of Heart Failure
A NA study of Heart Failure and Heart Failure With Reduced Ejection Fraction, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- NA
- Development phase
- 2,358
- Enrollment target
- 20
- Study locations
NCT03387813 is a NA study of Heart Failure and Heart Failure With Reduced Ejection Fraction that has completed, run by Abbott Medical Devices. The registered enrollment target is 2,358 participants, above the 2,043-participant average among 397 other Heart Failure trials with a reported enrollment target (15% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT03387813, a NA study of Heart Failure and Heart Failure With Reduced Ejection Fraction, has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- NA
- Development phase
- 2,358 participants
- Enrollment target
- 20
- Study locations
Study Summary
The GUIDE-HF IDE clinical trial is intended to demonstrate the effectiveness of the CardioMEMS™ HF System in an expanded patient population including heart failure (HF) patients outside of the present indication, but at risk for future HF events or mortality.
Conditions Studied
Interventions
- DEVICE CardioMEMS™ HF System
Study Locations (20)
California
- John Muir Medical Center - Concord
- Adventist Health St. Helena - Deer Park
- Scripps Health - La Jolla
- University of California at San Diego (UCSD) Medical Center - La Jolla
- USC University Hospital - Los Angeles
- Ronald Reagan UCLA Medical Center - Los Angeles
- Eisenhower Medical Center - Rancho Mirage
- Sutter Medical Center, Sacramento - Sacramento
- Mercy Medical Group - Cardiology - Sacramento
- San Diego Cardiac Center - San Diego
- California Pacific Medical Center - Van Ness Campus - San Francisco
- Ventura Cardiology Consultants - Ventura
Arizona
- Banner-University Medical Center Phoenix - Phoenix
- Arizona Cardiovascular Research Center - Phoenix
- Phoenix Cardiovascular Research Group - Phoenix
- University of Arizona - Tucson
Arkansas
- Washington Regional Medical Center - Fayetteville
- Baptist Health Medical Center - Little Rock
- Arkansas Heart Hospital - Little Rock
Colorado
- University of Colorado Hospital - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,358 participants |
| Start Date | 2018-03-15 |
| Est. Completion | 2023-05-17 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03387813
The ClinicalTrials.gov registry entry for NCT03387813 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 2,358 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 2,043-participant average among 397 other Heart Failure trials with a reported enrollment target (15% higher). The listed sponsor is Abbott Medical Devices, which has 261 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which CardioMEMS™ HF System is the first listed.
NCT03387813 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Arizona, Arkansas.
Frequently Asked Questions
What is clinical trial NCT03387813 about?
NCT03387813 is a clinical study titled "Hemodynamic-GUIDEd Management of Heart Failure". The GUIDE-HF IDE clinical trial is intended to demonstrate the effectiveness of the CardioMEMS™ HF System in an expanded patient population including heart failure (HF) patients outside of the present indication, but at risk for future HF events or mortality.
What is the current status of trial NCT03387813?
This trial is currently completed. It is a NA study. The enrollment target is 2,358 participants. The study started on 2018-03-15. Estimated completion is 2023-05-17.
What conditions does trial NCT03387813 study?
This clinical trial studies the following conditions: Heart Failure, Heart Failure With Reduced Ejection Fraction, Heart Failure, Diastolic, Heart Failure, Systolic, Heart Failure With Normal Ejection Fraction.
What interventions are being tested in trial NCT03387813?
The interventions under investigation include: CardioMEMS™ HF System (DEVICE).
Who is sponsoring clinical trial NCT03387813?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03387813 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Early Feasibility Study of the NORM™ System in Heart Failure Patients (FUTURE-HFII)
RECRUITING · NA
-
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
RECRUITING · NA
-
iCardia4HF: Multi-component mHealth Intervention for Patients With Heart Failure
RECRUITING · NA
-
Optimizing Heart Failure Therapies Among Patients With Limited Access in Denver
RECRUITING · NA
-
Hemodynamic Monitoring to Prevent Adverse Events foLlowing cardiOgenic Shock Trial
RECRUITING · NA
-
Effect of a Quality Improvement Initiative to Address Social Determinants of Health on Rehospitalization Rates in Patients With Heart Failure
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.